PHARMACEUTICAL 2026

Monopar Therapeutics
Rank 2 of 178

Monopar Therapeutics



PHARMACEUTICAL 2026

Monopar Therapeutics
Rank 2 of 178

Monopar Therapeutics

The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 223% points.The greatest weakness of Monopar Therapeutics is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 439%, being 209% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	140,463
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,735
Liabilities, Non-Current	155
Other Assets	255
Other Compr. Net Income	95
Other Expenses	0
Other Liabilities	0
Other Net Income	2,988
Other Revenues	0
Property and Equipment	0
Research and Development	9,904
Selling, General and Administrative Expense	6,800

Output Variable	Value in 1000 USD
Assets	140,718
Liabilities	2,890
Expenses	16,704
Revenues	0
Stockholders Equity	137,828
Net Income	-13,717
Comprehensive Net Income	-13,669
BaseVar	81,698
ECR before LimitedLiability	399%
Economic Capital Ratio	439%